Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Wockhardt s Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance .